Triciribine (Synonyms: 曲西立滨; API-2; NSC 154020; TCN)

目录号: HY-15457 纯度: 98.62%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Triciribine 是一种 DNA 合成 (DNA synthesis) 抑制剂，也抑制 Akt 和 HIV-1/2，IC₅₀ 分别为 130 nM 和 0.02-0.46 μM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Triciribine Chemical Structure

CAS No. : 35943-35-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥921	In-stock
1 mg	￥380	In-stock
5 mg	￥837	In-stock
10 mg	￥1150	In-stock
25 mg	￥2100	In-stock
50 mg	￥3360	In-stock
100 mg	￥5200	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Triciribine:

Triciribine phosphate 询价

MCE 顾客使用本产品发表的 21 篇科研文献

: Triciribine purchased from MCE. Usage Cited in: Stem Cell Res Ther. 2018 Mar 1;9(1):52. [Abstract]; Signaling protein expression detected by western blotting and quantified by densitometry with or without Triciribine.

: Triciribine purchased from MCE. Usage Cited in: Biochem Biophys Res Commun. 2017 Nov 4;493(1):286-290. [Abstract]; API-2 apparently inhibits insulin induced phosphorylation of Akt S473 in a dose dependent manner.

: Triciribine purchased from MCE. Usage Cited in: Biochem Biophys Res Commun. 2017 Nov 4;493(1):286-290. [Abstract]; Inhibition of pAkt by API-2 effectively prevents K145 induced increasing phosphorylation of FoxO1 in response to insulin. API-2 also significantly reverses K145 suppressed PEPCK and G6Pase mRNA and protein expression.

Triciribine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Akt 亚型特异性产品:

查看所有亚型

Akt Akt1 Akt2 Akt3

查看 HIV 亚型特异性产品:

查看所有亚型

HIV HIV-1 HIV-2

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Triciribine is a DNA synthesis inhibitor, also inhibits Akt and HIV-1/2 with IC₅₀ of 130 nM, and 0.02-0.46 μM, respectively.

IC₅₀ & Target^[1]^[2]^[3]

DNA synthesis

HIV-1

0.02-0.46 μM (IC₅₀)

HIV-2

0.02-0.46 μM (IC₅₀)

Akt

130 nM (IC₅₀, cell assay)

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
184B5	GI₅₀	16.96 μM Compound: 5	Cytotoxicity against human 184B5 cells at 20 uM chloroquine by SRB assay Cytotoxicity against human 184B5 cells at 20 uM chloroquine by SRB assay	[PMID: 18691894]
184B5	GI₅₀	34 μM Compound: 5	Cytotoxicity against human 184B5 cells at 10 uM chloroquine by SRB assay Cytotoxicity against human 184B5 cells at 10 uM chloroquine by SRB assay	[PMID: 18691894]
184B5	GI₅₀	40 μM Compound: 5	Cytotoxicity against human 184B5 cells by SRB assay Cytotoxicity against human 184B5 cells by SRB assay	[PMID: 18691894]
AA5	IC₅₀	< 0.17 μM Compound: TCN	Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
AA5	IC₅₀	< 0.17 μM Compound: TCN	Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
AA5	IC₅₀	< 0.17 μM Compound: TCN	Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
AA5	IC₅₀	> 53.1 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
AA5	IC₅₀	> 53.1 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
AA5	IC₅₀	> 53.1 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
AA5	IC₅₀	> 53.1 μM Compound: TCN	Cytotoxicity against human AA5 cells by MTS assay Cytotoxicity against human AA5 cells by MTS assay	[PMID: 20086149]
BSC-1	IC₅₀	23 μM Compound: TCN	Antiviral activity against HSV-1 was determined using BSC-1 cells by an enzyme-linked immunosorbent assay (ELISA) Antiviral activity against HSV-1 was determined using BSC-1 cells by an enzyme-linked immunosorbent assay (ELISA)	[PMID: 10882373]
BSC-1	IC₅₀	23 μM Compound: Triciribine(TCN)	Antiviral activity was tested using an enzyme-linked immunosorbent assay (ELISA) to detect HSV-1 (herpes simplex virus type 1) using BSC-1 cells Antiviral activity was tested using an enzyme-linked immunosorbent assay (ELISA) to detect HSV-1 (herpes simplex virus type 1) using BSC-1 cells	[PMID: 10882371]
CEM-SS	CC₅₀	77.3 μM Compound: TCN	Cytotoxicity against human CEM-SS cells infected with Human immunodeficiency virus 2 ROD by MTS assay Cytotoxicity against human CEM-SS cells infected with Human immunodeficiency virus 2 ROD by MTS assay	[PMID: 20086149]
CEM-SS	CC₅₀	85.8 μM Compound: TCN	Cytotoxicity against human CEM-SS cells by MTS assay Cytotoxicity against human CEM-SS cells by MTS assay	[PMID: 20086149]
CEM-SS	CC₅₀	88.5 μM Compound: TCN	Cytotoxicity against human CEM-SS cells infected with Human immunodeficiency virus 1 SK1 by MTS assay Cytotoxicity against human CEM-SS cells infected with Human immunodeficiency virus 1 SK1 by MTS assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.04 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B expressing nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B expressing nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.08 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.13 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 SK1 infected in human CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 SK1 infected in human CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.19 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
CEM-SS	IC₅₀	0.2 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 harboring plasmid NL4-3 infected in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 harboring plasmid NL4-3 infected in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.24 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
CEM-SS	IC₅₀	0.29 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.3 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.33 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 D1 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 D1 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.5 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 A7 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 A7 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	1.4 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 2 ROD infected in human CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 2 ROD infected in human CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	< 0.01 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
CEM-SS	IC₅₀	> 10 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 harboring plasmid TAK-1 infected in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 harboring plasmid TAK-1 infected in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	> 10 μM Compound: TCN	Ratio of IC50 for Human immunodeficiency virus 1 H10 infected in CEM-SS cells to IC50 for Human immunodeficiency virus 1 3B infected in CEM-SS cells Ratio of IC50 for Human immunodeficiency virus 1 H10 infected in CEM-SS cells to IC50 for Human immunodeficiency virus 1 3B infected in CEM-SS cells	[PMID: 20086149]
CEM-SS	IC₅₀	> 100 μM Compound: TCN	Visual cytotoxicity was scored on CEM-SS cells Visual cytotoxicity was scored on CEM-SS cells	[PMID: 10882373]
CEM-SS	IC₅₀	> 100 μM Compound: Triciribine(TCN)	Tested for visual cytotoxicity on uninfected CEM-SS cells Tested for visual cytotoxicity on uninfected CEM-SS cells	[PMID: 10882371]
CEM-SS	IC₅₀	> 3.13 μM Compound: TCN	Cytotoxicity against human CEM-SS cells by MTS assay Cytotoxicity against human CEM-SS cells by MTS assay	[PMID: 20086149]
CEM-SS	IC₅₀	> 30 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 A12 harboring Tyr127His, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 A12 harboring Tyr127His, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	> 30 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 H10 harboring Tyr127His, Gly140Glu, Glu149Lys, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 H10 harboring Tyr127His, Gly140Glu, Glu149Lys, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	CC₅₀	19.6 μM Compound: TCN	Cytotoxicity against human H9 cells by MTS assay Cytotoxicity against human H9 cells by MTS assay	[PMID: 20086149]
H9	IC₅₀	0.036 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 SK1 infected in human H9 cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 SK1 infected in human H9 cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	IC₅₀	1.53 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	IC₅₀	16.3 μM Compound: TCN	Cytotoxicity against human H9 cells by MTS assay Cytotoxicity against human H9 cells by MTS assay	[PMID: 20086149]
H9	IC₅₀	< 0.1 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
H9	IC₅₀	< 0.1 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	IC₅₀	< 0.1 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	IC₅₀	< 0.1 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
H9	IC₅₀	< 0.1 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	IC₅₀	> 31.3 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
H9	IC₅₀	> 31.3 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
HFF	IC₅₀	100 μM Compound: 8	Visual cytotoxicity was determined in uninfected HFF cells using plaque assay Visual cytotoxicity was determined in uninfected HFF cells using plaque assay	[PMID: 15916436]
HFF	IC₅₀	100 μM Compound: TCN	Visual cytotoxicity was scored on uninfected HFF cells Visual cytotoxicity was scored on uninfected HFF cells	[PMID: 10882373]
HFF	IC₅₀	100 μM Compound: Triciribine(TCN)	Tested for visual cytotoxicity on uninfected HFF cells Tested for visual cytotoxicity on uninfected HFF cells	[PMID: 10882371]
HFF	IC₅₀	2.5 μM Compound: TCN	Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells	[PMID: 10882373]
HFF	IC₅₀	2.5 μM Compound: Triciribine(TCN)	HCMV plaque assay was performed using HFF cells and effect was calculated as a percentage of reduction in number of plaques HCMV plaque assay was performed using HFF cells and effect was calculated as a percentage of reduction in number of plaques	[PMID: 10882371]
Huh-7	CC₅₀	> 300 μM Compound: 3	Cytotoxicity using HCV replicon assay Cytotoxicity using HCV replicon assay	[PMID: 15177464]
Huh-7	EC₅₀	2 μM Compound: 3	Compound was tested for its ability to inhibit hepatitis C viral RNA replication in Huh-7 cells (human hepatoma cells) Compound was tested for its ability to inhibit hepatitis C viral RNA replication in Huh-7 cells (human hepatoma cells)	[PMID: 15177464]
KB	IC₅₀	100 μM Compound: 8	Inhibitory concentration was determined for KB cell growth Inhibitory concentration was determined for KB cell growth	[PMID: 15916436]
KB	IC₅₀	> 100 μM Compound: TCN	Cytotoxicity measured as Inhibition of KB cell growth was assessed. Cytotoxicity measured as Inhibition of KB cell growth was assessed.	[PMID: 10882373]
KB	IC₅₀	> 100 μM Compound: Triciribine(TCN)	Inhibition of KB cell growth was assessed Inhibition of KB cell growth was assessed	[PMID: 10882371]
L1210	IC₅₀	0.035 μM Compound: Triciribine(TCN)	Tested in vitro for cytotoxicity against murine L1210 leukemic cells Tested in vitro for cytotoxicity against murine L1210 leukemic cells	[PMID: 10882371]
MCF7	GI₅₀	0.05 μM Compound: 5	Cytotoxicity against human MCF7 cells in presence of 20 uM chloroquine by SRB assay Cytotoxicity against human MCF7 cells in presence of 20 uM chloroquine by SRB assay	[PMID: 18691894]
MCF7	GI₅₀	0.56 μM Compound: 5	Cytotoxicity against human MCF7 cells in presence of 10 uM chloroquine by SRB assay Cytotoxicity against human MCF7 cells in presence of 10 uM chloroquine by SRB assay	[PMID: 18691894]
MCF7	GI₅₀	3.64 μM Compound: 5	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 18691894]
MDA-MB-231	GI₅₀	0.69 μM Compound: 5	Cytotoxicity against human MDA-MB-231 cells in presence of 20 uM chloroquine by SRB assay Cytotoxicity against human MDA-MB-231 cells in presence of 20 uM chloroquine by SRB assay	[PMID: 18691894]
MDA-MB-231	GI₅₀	37 μM Compound: 5	Cytotoxicity against human MDA-MB-231 cells in presence of 10 uM chloroquine by SRB assay Cytotoxicity against human MDA-MB-231 cells in presence of 10 uM chloroquine by SRB assay	[PMID: 18691894]
MDA-MB-231	GI₅₀	50.15 μM Compound: 5	Cytotoxicity against human MDA-MB-231 cells by SRB assay Cytotoxicity against human MDA-MB-231 cells by SRB assay	[PMID: 18691894]
MDA-MB-468	GI₅₀	10.29 μM Compound: 5	Cytotoxicity against human MDA-MB-468 cells in presence of 20 uM chloroquine by SRB assay Cytotoxicity against human MDA-MB-468 cells in presence of 20 uM chloroquine by SRB assay	[PMID: 18691894]
MDA-MB-468	GI₅₀	20.45 μM Compound: 5	Cytotoxicity against human MDA-MB-468 cells in presence of 10 uM chloroquine by SRB assay Cytotoxicity against human MDA-MB-468 cells in presence of 10 uM chloroquine by SRB assay	[PMID: 18691894]
MDA-MB-468	GI₅₀	43.53 μM Compound: 5	Cytotoxicity against human MDA-MB-468 cells by SRB assay Cytotoxicity against human MDA-MB-468 cells by SRB assay	[PMID: 18691894]
U1	CC₅₀	0.28 μM Compound: TCN	Cytotoxicity against human U1 cells infected with latent Human immunodeficiency virus 1 by MTS assay Cytotoxicity against human U1 cells infected with latent Human immunodeficiency virus 1 by MTS assay	[PMID: 20086149]
U1	CC₅₀	0.28 μM Compound: TCN	Cytotoxicity against human U1 cells infected with latent Human immunodeficiency virus 1 by MTS assay in presence of tumor necrosis factor alpha Cytotoxicity against human U1 cells infected with latent Human immunodeficiency virus 1 by MTS assay in presence of tumor necrosis factor alpha	[PMID: 20086149]
U1	IC₅₀	0.23 μM Compound: TCN	Antiviral activity against Human immunodeficiency virus 1 infected in human U1 cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 infected in human U1 cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]

体外研究
(In Vitro)

核苷类似物 Triciribine (TCN) 是一种嘌呤类似物，最初被证明可以抑制 DNA 合成。Triciribine 选择性地抑制所有三种 Akt 同工型的磷酸化和激活。在 10 μM 的浓度下，Triciribine 抑制 Akt 在 Thr308 和 Ser473 位点的磷酸化。Triciribine 有效抑制 PC-3 细胞中 Akt 的磷酸化，从而抑制其催化活性^[1]。 Akt 抑制剂 Triciribine (TCN) 对人细胞系 U87MG 的抑制效果不佳，但以分级依赖的方式抑制其他星形胶质瘤细胞系。WHO II K1861-10 细胞系的抑制不完全 (最大抑制率为 69%) ，其对 Triciribine 的 GI₅₀ 值为 1.7 μM。在 KR158 细胞中，Triciribine 在 1-10 μM 时显示出最大的生长抑制效果，并在 100 μM 时将 Akt 及其下游 p70S6K 的磷酸化抑制至基础水平 (IC₅₀=130 nM)^[2]。 Triciribine (TCN) 是一种具有已知抗肿瘤活性的新型三环化合物。通过合体斑块测定法，Triciribine 在 0.01-0.02 μM 时对 HIV-1 有效。通过微量滴定 XTT 测定法，Triciribine 对一系列 HIV-1 和 HIV-2 毒株的 IC₅₀ 值在 0.02 到 0.46 μM 之间^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Triciribine (TCBN) 处理在缺氧 14 天后进行，持续 7 天直至达到 21 天缺氧，能够通过免疫组化和 Western 分析显示的血管增厚现象得到逆转。另一方面，Rapamycin 处理未能预防缺氧诱导的肺泡出血和充血。Triciribine 部分抑制了血管的进行性修剪。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

320.30

Formula

C₁₃H₁₆N₆O₄

CAS 号

35943-35-2

性状

固体

颜色

Light yellow to khaki

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (312.21 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.1221 mL	15.6104 mL	31.2207 mL
5 mM	0.6244 mL	3.1221 mL	6.2441 mL
10 mM	0.3122 mL	1.5610 mL	3.1221 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.81 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.81 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.81 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.81%

选择批次：

Data Sheet (656 KB) SDS (393 KB)

COA (291 KB) LCMS (112 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Dieterle A, et al. The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Int J Cancer. 2009 Aug 15;125(4):932-41. [Content Brief]

[2]. Gürsel DB, et al. Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma. Neuro Oncol. 2011 Jun;13(6):610-21 [Content Brief]

[3]. Kucera LS, et al. Activity of triciribine and triciribine-5'-monophosphate against human immunodeficiency virus types 1 and 2. AIDS Res Hum Retroviruses. 1993 Apr;9(4):307-14. [Content Brief]

[4]. Abdalla M, et al. The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis. Br J Pharmacol. 2015 Aug;172(16):4173-88. [Content Brief]

Cell Assay ^[2]	The human SF295 and U87MG GBM lines and the mouse K1861-10, KR158, and KR130G astrocytoma lines are plated at a density of 2500 cells/100 µL complete media in 96-well plates. Mouse primary astrocytes are plated at 5000 cells/100 µL. Cells are treated in triplicate with serial dilutions of inhibitors (The inhibitors tested are PI-103, Triciribine and Rapamycin) ranging from µM to pM. Cell proliferation is measured after 3 days using the Alamar Blue assay on a Novostar plate reader. Values for 50% inhibitory concentration (IC₅₀) and 50% growth inhibitory concentration (GI₅₀) are calculated using standard procedures in GraphPad Prism v4 and Microsoft Excel^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[4]	Mice^[4] Akt1^+/+ and Akt1^−/− mice are subjected to normoxia or hypoxia (10% O₂) for 7 and 14 days (n=2-6 mice per group). Noteworthy, high mortality is observed in Akt1^−/− mice exposed to hypoxia longer than 14-16 days. For pharmacological inhibition studies, Akt1^+/+ mice, subjected to normoxia or chronic hypoxia for 14 days, received daily i.p. injection of saline, Triciribine (0.5 mg/kg per day) or Rapamycin (1.5 mg/kg per day) for 7 days, and the total continuous exposure to hypoxia or normoxia is 21 days (n=6-8 mice per group). Pharmacological inhibitors are administered daily while the mice are maintained in the hypoxia chamber to minimize exposure to air and spontaneous reversal of pulmonary remodelling. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Dieterle A, et al. The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Int J Cancer. 2009 Aug 15;125(4):932-41. [Content Brief] [2]. Gürsel DB, et al. Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma. Neuro Oncol. 2011 Jun;13(6):610-21 [Content Brief] [3]. Kucera LS, et al. Activity of triciribine and triciribine-5'-monophosphate against human immunodeficiency virus types 1 and 2. AIDS Res Hum Retroviruses. 1993 Apr;9(4):307-14. [Content Brief] [4]. Abdalla M, et al. The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis. Br J Pharmacol. 2015 Aug;172(16):4173-88. [Content Brief]

Triciribine 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.1221 mL	15.6104 mL	31.2207 mL	78.0518 mL
	5 mM	0.6244 mL	3.1221 mL	6.2441 mL	15.6104 mL
	10 mM	0.3122 mL	1.5610 mL	3.1221 mL	7.8052 mL
	15 mM	0.2081 mL	1.0407 mL	2.0814 mL	5.2035 mL
	20 mM	0.1561 mL	0.7805 mL	1.5610 mL	3.9026 mL
	25 mM	0.1249 mL	0.6244 mL	1.2488 mL	3.1221 mL
	30 mM	0.1041 mL	0.5203 mL	1.0407 mL	2.6017 mL
	40 mM	0.0781 mL	0.3903 mL	0.7805 mL	1.9513 mL
	50 mM	0.0624 mL	0.3122 mL	0.6244 mL	1.5610 mL
	60 mM	0.0520 mL	0.2602 mL	0.5203 mL	1.3009 mL
	80 mM	0.0390 mL	0.1951 mL	0.3903 mL	0.9756 mL
	100 mM	0.0312 mL	0.1561 mL	0.3122 mL	0.7805 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Triciribine35943-35-2API-2 NSC 154020 TCNAPI2API 2NSC154020NSC 154020NSC-154020DNA/RNA SynthesisAktHIVPKBProtein kinase BHuman immunodeficiency virusInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Triciribine (Synonyms: 曲西立滨; API-2; NSC 154020; TCN)

Customer Review

Other Forms of Triciribine:

MCE 顾客使用本产品发表的 21 篇科研文献

Triciribine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Akt 亚型特异性产品:

查看 HIV 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Triciribine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Triciribine (Synonyms: 曲西立滨; API-2; NSC 154020; TCN)

Customer Review

Other Forms of Triciribine:

Triciribine 相关抗体

MCE 顾客使用本产品发表的 21 篇科研文献

Triciribine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Akt 亚型特异性产品:

查看 HIV 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Triciribine 相关抗体:

摩尔计算器

稀释计算器

Triciribine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z